Arrowhead Pharmaceuticals (ARWR) Given a $2.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $2.00 price objective on Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a report published on Tuesday morning. The firm currently has a hold rating on the biotechnology company’s stock.

ARWR has been the subject of several other research reports. ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a strong sell rating to a sell rating in a research report on Thursday, August 24th. William Blair raised shares of Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a report on Monday, September 18th. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, December 2nd. Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 price objective for the company in a report on Monday, November 27th. Finally, Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $3.17.

Arrowhead Pharmaceuticals (ARWR) opened at $3.55 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.84 and a current ratio of 3.84. Arrowhead Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $4.54.

Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in Arrowhead Pharmaceuticals by 3.4% in the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after buying an additional 21,654 shares during the last quarter. LMR Partners LLP acquired a new position in Arrowhead Pharmaceuticals during the second quarter worth $467,000. Virtu KCG Holdings LLC raised its stake in Arrowhead Pharmaceuticals by 115.6% during the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 53,215 shares in the last quarter. ING Groep NV acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth $3,500,000. Finally, Schwab Charles Investment Management Inc. raised its stake in Arrowhead Pharmaceuticals by 10.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after acquiring an additional 16,103 shares in the last quarter. 20.20% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Arrowhead Pharmaceuticals (ARWR) Given a $2.00 Price Target at Cantor Fitzgerald” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/13/arrowhead-pharmaceuticals-arwr-given-a-2-00-price-target-at-cantor-fitzgerald.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

What are top analysts saying about Arrowhead Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Arrowhead Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit